Calcium Channel Blocker Management

Introduction to Calcium Channel Blockers

Calcium channel blockers (CCBs) are divided into three chemically distinct subclasses, each with different pharmacological profiles, including dihydropyridines, benzothiazepines, and phenylalkylamines, with varying effects on heart rate, AV conduction, and peripheral vasodilation 1

The American Heart Association recommends amlodipine as a first-line treatment for hypertension due to its better tolerability and fewer side effects, with a typical dosage of 5-10 mg once daily 1
Diltiazem is an alternative option for hypertension management, particularly in patients with coronary disease, with a recommended dosage of 120-360 mg daily (extended release) 1, 2

Diltiazem or verapamil are recommended for angina management in patients with normal left ventricular function, due to their ability to reduce heart rate and myocardial oxygen demand 1, 2
Any CCB may be effective for variant/vasospastic angina, although the choice of agent should be individualized based on patient-specific factors 2

Verapamil and diltiazem should be avoided in patients with heart failure or severe left ventricular dysfunction, due to their negative inotropic effects 1
Significant AV conduction abnormalities are a contraindication for verapamil and diltiazem, due to their potential to exacerbate conduction disturbances 3
Concurrent beta-blocker therapy requires caution when using verapamil or diltiazem, due to the risk of bradycardia 1

Amlodipine is typically initiated at a dosage of 5-10 mg once daily, with a longer half-life allowing for once-daily dosing and effective 24-hour blood pressure control 1
Diltiazem is typically initiated at a dosage of 120-360 mg daily (extended release), with a better safety profile in coronary disease and less reflex tachycardia than dihydropyridines 1, 2

Blood pressure should be checked within 1-2 weeks of switching to a new CCB, with ongoing monitoring for new side effects and changes in heart rate or ECG 1
Patients should be aware of the potential for drug interactions, particularly with beta-blockers when using verapamil or diltiazem, and should be monitored closely for signs of adverse events 3, 2
The American College of Cardiology recommends strategies to manage amlodipine-induced edema, including switching to a non-dihydropyridine calcium channel blocker, using a lower dose of amlodipine, or adding beta-blockers, ACE inhibitors, ARB, or beta-blockers to allow for amlodipine dose reduction while maintaining blood pressure control 1, 4

Blood pressure returns to baseline gradually over 7-10 days after amlodipine discontinuation, with no rebound hypertension, but alternative therapy should be in place, according to clinical guidelines 5
Verapamil and diltiazem should be avoided in patients with pulmonary edema or severe LV dysfunction, as recommended by the American College of Cardiology 1, 4, 6